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The HIV Vaccine Trials Network has as its central mission,
the implementation of clinical trials of candidate vaccine
products (immunogens, vector, delivery, adjuvants) that
induce immunologic responses relevant to preventing
HIV infection and/or controlling HIV disease progression.
The research agenda targets evaluation of candidates at all
stages of product development from phase 1 first in
human trials to proof of concept and efficacy trials. Inno-
vative trial designs are driven by investigators and statisti-
cians to efficiently advance products and information that
seeks fundamental insight into correlates of protective
immunity. HVTN laboratories quantitate adaptive and
innate immune responses employing highly reproducible
and standardized endpoint assays that meet GLP valida-
tion standards for core assessment as well as exploratory
assays to understand correlate mechanisms. Currently 24
HIV vaccine candidates are slated for evaluation over the
next 24 months including proof of concept and expanded
phase 2 evaluation in preparation for larger efficacy trials
in the 2007–2008 time period.
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